Dr Voorhees Highlights Trispecifics and Frontline CAR T in Myeloma

Peter M. Voorhees, MD, a multiple myeloma specialist at Atrium Health/Levine Cancer Institute in Charlotte, North Carolina, shares key insights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, specifically in the multiple myeloma space.

Early data from a trispecific antibody targeting GPRC5D and BCMA show promise in reducing antigen escape, a common resistance mechanism with bispecifics. By hitting 2 antigens at once, these therapies may offer more durable responses.

Voorhees also discussed 2 ongoing trials exploring ciltacabtagene autoleucel (cilta-cel; Carvykti) in newly diagnosed patients with multiple myeloma.

TRANSCRIPTION:

0:10 | There's a lot of interest in the trispecific antibody results that [were] being presented on Tuesday [at ASCO 2025]. So specifically, this is a trispecific antibody that's targeting both GPRC5D and BCMA on the myeloma cell. We know from correlative work that when patients are treated with a BCMA-directed bispecific antibody, and in particular, a GPRC5D-targeted bispecific antibody, that at the time of relapse, you see a frequent proportion of patients who have mutations or deletions of the targets.

1:00 | This antigen loss mechanism of resistance is very real with the bispecifics. The hope is that by targeting 2 antigens, the likelihood of antigen escape is going to be less. I think at least the initial data from the trispecific antibody study really look quite good.

1:20 | With regards to my presentation, you know, and you know this issue of T-cell fitness and being able to better manipulate the effector to target ratio going into cilta-cel infusion, there are the CARTITUDE-5 [NCT04923893] and CARTITUDE-6 studies [NCT05257083] that are ongoing. So these are studies that are looking at cell to cell therapy as part of frontline treatment for patients with newly diagnosed multiple myeloma, and those studies are going to better, help us understand what kind of impact cilta-cel has and in that group of patients, and CARTITUDE-6 in particular, is looking to see if cilta-cel can replace transplant as part of the frontline paradigm for newly diagnosed patients.